Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024
Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024
SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation.Expanded State Medicaid Access for GIMOTI
爲GIMOTI擴大了州級醫療補助的獲取途徑
Achieved highest ever monthly GIMOTI prescription fills in May 2024
2024年5月份GIMOTI處方的填充量創下歷史新高
Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer
晉升財務副總裁馬克·科維斯基爲致富金融官員(臨時代碼)
SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation.
加利福尼亞州索拉納海灘，2024年6月17日，全球新聞通訊社——專注於治療胃腸（GI）疾病，側重於GIMOTI（甲氧氯普胺）鼻噴劑的特殊藥品公司Evoke Pharma Inc（納斯達克股票代碼：EVOK）宣佈了有關其業務和商業增長策略的更新。Evoke以確保GIMOTI實現最大市場接觸爲核心，繼續全力實施其擴大產品淨銷售額的計劃。該更新概述了Evoke戰略藍圖的關鍵領域以及有關其實施的積極進展情況。
譯文內容由第三人軟體翻譯。